mk-6482 to treat renal cell carcinoma in von hippel-lindau disease patients
Published 3 years ago • 330 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
2:15
mk-6482 shows promise in von hippel-lindau disease-associated renal cell carcinoma
-
1:48
dr. jonasch on next steps with mk-6482 in von hippel-lindau disease–associated rcc
-
1:16
dr. jonasch on the safety profile of mk-6482 in von hippel-lindau disease–associated rcc
-
2:48
oral hif-2 α inhibitor mk-6482 in patients with advanced clear cell renal cell carcinoma
-
4:53
data from von-hippel-lindau clinical trial shows promise for hif-2a inhibitor
-
2:55
what is von hippel-lindau disease?
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482
-
58:42
"von hippel-lindau disease", a scientific lecture by nobel laureate william g. kaelin
-
6:22
von hippel lindau disease - case based discussion usmle step 1 pathology
-
5:20
treatment strategies for von hippel-lindau syndrome
-
4:44
pathophysiology and management of von hippel-lindau syndrome
-
13:17
belzutifan for von hippel-lindau syndrome
-
9:35
litespark-004: 36 month follow-up of belzutifan in von hippel-lindau syndrome
-
5:12
von hippel lindau disease || kidney || renal
-
5:30
systemic therapy with belzutifan approved for von hippel lindau-associated cancers
-
2:09
promising real-world outcomes of belzutifan in vhl-associated tumors
-
0:55
what is the connection between von hippel-lindau syndrome and kidney cancer?
-
1:19
von hippel lindau disease
-
4:39
clear cell rcc: vhl/hif pathway